Search

• ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017

  Media

  ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017/

  First published: 20 July 2017

• GSK to showcase scientific advances and progress in oncology at ASCO and EHA

  Media

  GSK will showcase innovative approaches to oncology R&D and cutting-edge science at the upcoming ASCO and EHA meetings.

  https://www.gsk.com/en-gb/media/press-releases/gsk-to-showcase-scientific-advances-and-progress-in-oncology-at-asco-and-eha/

  First published: 01 June 2021

• GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours

  Media

  GARNET study demonstrated objective response rate of 41.6% across dMMR solid tumours

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-accelerated-approval-for-jemperli-dostarlimab-gxly-for-adult-patients-with-mismatch-repair-deficient-dmmr-recurrent-or-advanced-solid-tumours/

  First published: 17 August 2021

• ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen

  Media

  ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen/

  First published: 18 November 2016

• Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer

  Media

  Only immuno-oncology combination to show statistically significant and clinically meaningful overall survival in overall population.

  https://www.gsk.com/en-gb/media/press-releases/positive-ruby-phase-iii-data-show-potential-for-jemperli-dostarlimab-combinations-in-more-patients-with-primary-advanced-or-recurrent-endometrial-cancer/

  First published: 16 March 2024

• 

  History and heritage

  Company

  It began when Plough Court Pharmacy was established in 1715. Discover GSK’s journey to the company we are today

  https://www.gsk.com/en-gb/company/history-and-heritage/

  First published: 27 February 2025

• 

  ‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics

  Behind the science magazine

  The world needs new antibiotics to combat AMR pathogens – but too few are invested in development.

  https://www.gsk.com/en-gb/behind-the-science-magazine/amr-antibiotics-resistance-superbugs-new-medicines/

  First published: 21 March 2025

• 

  Annual General Meeting

  Investors

  Typically we hold our AGM in London every May. Directors who attend are formally available for questions, during the meeting.

  https://www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/

  First published: 24 March 2025

• GSK unveils latest research advances demonstrating strength of its portfolio and pipeline at ASCO and EHA

  Media

  GSK plc will present 25 abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

  https://www.gsk.com/en-gb/media/press-releases/gsk-unveils-latest-research-advances-at-asco-and-eha/

  First published: 26 May 2022

• New data at ASCO showcases the transformational potential of GSK's oncology portfolio

  Media

  Pivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III trials.

  https://www.gsk.com/en-gb/media/press-releases/new-data-at-asco-showcases-the-transformational-potential-of-gsks-oncology-portfolio/

  First published: 23 May 2024